Merck, ODAC Mostly Like US FDA's Point-Counterpoint Briefing Document

 
• By Derrick Gingery
StacksOfPapers_1200x675
The point-counterpoint format is intent on reducing duplication in US FDA advisory committee briefing documents. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers